Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Informed Consent

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44398   clinical trials with a EudraCT protocol, of which   7410   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28,977 result(s) found for: Informed Consent. Displaying page 786 of 1,449.
    «« First « Previous 782  783  784  785  786  787  788  789  790  Next» Last»»
    EudraCT Number: 2017-003377-34 Sponsor Protocol Number: 54767414ALL2005 Start Date*: 2018-07-31
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age With Relapsed/Refractory Precursor B-cell o...
    Medical condition: Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    20.0 100000004864 10066110 T-cell lymphoblastic leukemia acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) FR (Completed) ES (Completed) SE (Completed) NL (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-003376-40 Sponsor Protocol Number: FAB122-CT-2001 Start Date*: 2021-08-10
    Sponsor Name:Ferrer Internacional, S.A.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IE (Completed) NL (Completed) DE (Completed) ES (Completed) PL (Completed) IT (Completed) SE (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004727-33 Sponsor Protocol Number: CY5032 Start Date*: 2022-10-28
    Sponsor Name:Cytokinetics Inc
    Full Title: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) SE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) PT (Ongoing) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003952-29 Sponsor Protocol Number: BAY63-2521/15681 Start Date*: 2015-08-25
    Sponsor Name:Bayer AG
    Full Title: Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (...
    Medical condition: Hypertension, Pulmonary
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) IT (Trial now transitioned) GB (Completed) DE (Trial now transitioned) ES (Prematurely Ended) PL (Completed) Outside EU/EEA BE (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-001845-42 Sponsor Protocol Number: TAK-788-3001 Start Date*: 2020-03-02
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR...
    Medical condition: Non-Small Cell Lung Cancer (NSCLC) with EGFR exon 20 insertion mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) GR (Completed) BE (Completed) ES (Completed) NL (Completed) AT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DK (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003726-23 Sponsor Protocol Number: 1346-0013 Start Date*: 2021-06-07
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of iclepertin once daily over 26 week treatment period in patients with schizophreni...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) FI (Completed) CZ (Completed) BE (Completed) LT (Completed) PT (Completed) AT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-002261-22 Sponsor Protocol Number: KTE-C19-107 Start Date*: 2018-09-11
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
    Medical condition: Relapsed/Refractory Diffuse Large B cell Lymphoma (r/r DLBCL).
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) BE (Completed) IT (Completed) ES (Ongoing) FR (Completed) SE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003960-20 Sponsor Protocol Number: NN7008-3543 Start Date*: 2009-06-26
    Sponsor Name:Novo Nordisk A/S
    Full Title: A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Prevention and Treatment of Bleeds in Previously Treated Subjects with Haemophilia A Sub-Trial: Safety and Efficacy ...
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    13.1 10010331 - Congenital, familial and genetic disorders 10018937 Haemophilia A LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-005060-10 Sponsor Protocol Number: NVG09B113 Start Date*: 2013-04-08
    Sponsor Name:Novagali Pharma S.A.S.
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-MASKED, 3 PARALLEL ARMS, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NOVA22007 1MG/ML (CICLOSPORIN/CYCLOSPORINE) EYE DROPS, EMULSION ADMINISTERED...
    Medical condition: Vernal Keratoconjunctivitis (VKC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10057383 Allergic keratoconjunctivitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed) DE (Completed) PT (Completed) ES (Completed) GR (Completed) HR (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001491-35 Sponsor Protocol Number: CB103-C-101 Start Date*: 2017-08-11
    Sponsor Name:Cellestia Biotech AG
    Full Title: A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adu...
    Medical condition: advanced or metastatic solid tumours and haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003455-21 Sponsor Protocol Number: GS-US-367-1171 Start Date*: 2016-02-12
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Di...
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    18.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-000526-21 Sponsor Protocol Number: 61186372NSC2002 Start Date*: 2023-02-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.
    Medical condition: Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-000817-20 Sponsor Protocol Number: 6002-EU-007 Start Date*: 2004-10-22
    Sponsor Name:Kyowa Hakko U.K. Limited
    Full Title: A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entac...
    Medical condition: Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) AT (Completed) LT (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002463-88 Sponsor Protocol Number: L00133 IV 301 (ORF) Start Date*: 2006-07-18
    Sponsor Name:Orfagen
    Full Title: Efficacy and safety of a human normal immunoglobulin product for intravenous administration (IVIg) in the treatment of dermatomyositis (DM) and polymyositis (PM): prospective, randomised, double-bl...
    Medical condition: Idiopathic DM and PM with insufficiently improved muscle strength under conventional therapy (Glucocorticosteroids associated with immunosuppressors).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-001307-11 Sponsor Protocol Number: A6061031 Start Date*: 2006-10-02
    Sponsor Name:Pfizer Ltd
    Full Title: A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATH...
    Medical condition: Diabetic Peripheral Neuropathy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012683 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) EE (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004767-34 Sponsor Protocol Number: C-05-25 Start Date*: 2006-03-28
    Sponsor Name:Alcon Research, Ltd.
    Full Title: A Six-Week, multicenter, randomized, double-masked study to evaluate the efficacy and safety of dosing once-daily Travoprost/Timolol in the morning vs. twice-daily Dorzolamide/Timolol in patients w...
    Medical condition: Open-angle glaucoma and ocular hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) ES (Completed) LV (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002243-25 Sponsor Protocol Number: CAAE581A2203E2 Start Date*: 2007-08-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis
    Medical condition: Osteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) FR (Completed) AT (Completed) ES (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-006182-88 Sponsor Protocol Number: CRAD001CDE16 Start Date*: 2009-03-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe
    Medical condition: Patients with histologically confirmed advanced (unresectable or metastatic) non syndromic NET from foregut, midgut and hindgut, with exclusion of pancreatic NET, who have progressed within 12 mont...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052399 Neuroendocrine tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014378-16 Sponsor Protocol Number: Bay 58-2667/14663 Start Date*: 2010-01-14
    Sponsor Name:Bayer Healthcare AG
    Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of Low Dose BAY 58-2667 (25 μg/h, 10 μg/h) Given Intravenously ...
    Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064653 Acute decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023210-31 Sponsor Protocol Number: Y52-52120-155 Start Date*: 2012-02-24
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNIT...
    Medical condition: NEUROGENIC DETRUSOR OVERACTIVITY
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) LT (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 782  783  784  785  786  787  788  789  790  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 10 03:26:13 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA